Role of STAT3 in Transformation and Drug Resistance in CML
about
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaBreast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasisA derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemiaOvercoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase.Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol MebutateGinkgetin Blocks Constitutive STAT3 Activation and Induces Apoptosis through Induction of SHP-1 and PTEN Tyrosine Phosphatases.Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.SZRD1 is a Novel Protein that Functions as a Potential Tumor Suppressor in Cervical Cancer.Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
P2860
Q35102414-30D0C74A-1BAD-42F7-A03A-845F9140C7AFQ35154624-48F2624F-1F70-4BCA-B706-AFDF4B93D679Q35865441-5EB7A41B-1410-44D3-849B-BA9C45743442Q36243367-DA2DF7C1-F8A8-4452-AF9A-ECE1FEFF3B22Q37109841-5FF4A7AA-5AB2-4B26-B763-203579264A60Q38716136-EADF88E1-B746-4EFF-A997-6F6F812027CDQ38750781-485BE8E1-BB85-49C5-BA4E-FF8965F33CBAQ38779744-438FB71A-6E99-4307-BD7B-8D61D560D16DQ40056618-7ED33D82-A3BE-466A-A463-D67511C1E018Q41439962-D3FF33C7-A252-474B-9D3E-E578F6F63390Q47117016-0627ECF6-56A5-4C2A-8B4D-7476CFCA90F1Q47140067-FEF5FAA8-BCF1-4C7A-A08A-54D52A5380EFQ54346297-0558547F-AAC1-417E-896C-6D6DBE90C34DQ55060633-3D225FBC-FF6B-453E-85CE-710B0580CF6EQ58742654-9560803C-76A6-4150-B62E-D3D6F85A7FF9
P2860
Role of STAT3 in Transformation and Drug Resistance in CML
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Role of STAT3 in Transformation and Drug Resistance in CML
@en
Role of STAT3 in Transformation and Drug Resistance in CML
@nl
type
label
Role of STAT3 in Transformation and Drug Resistance in CML
@en
Role of STAT3 in Transformation and Drug Resistance in CML
@nl
prefLabel
Role of STAT3 in Transformation and Drug Resistance in CML
@en
Role of STAT3 in Transformation and Drug Resistance in CML
@nl
P2093
P2860
P356
P1476
Role of STAT3 in Transformation and Drug Resistance in CML
@en
P2093
Joel H Tolentino
Lori A Hazlehurst
Rajesh R Nair
P2860
P356
10.3389/FONC.2012.00030
P577
2012-04-10T00:00:00Z